| * |
failure of attempt
to perform gene deletion by double homologous replacement |
changes in ploidy indicative of essentiality; may be a technical
failure |
30 |
TR, A2-A2REL, SODB1, LACK, PK, CRN12, TOR1, TOR2, SPASE I, MYO21, HSLU1, LHR1, HUS1, HEMAC, ENDOG, ASNA, ARP, RAD51-6, AIRK, LMIT1, RAD50, TYRRS, ABC3, RAB5A, RAB5B, TWF, SIR2RP2, SODA, ACECS, CPN10
|
15 |
TC52, DHOD, GALE, DHFR-TS, ECH1, SUB2, GPI8, GPI12, CRT, IP3R, RPA2, GALF, CYP51, STI1
|
| ** |
facilitated null mutant; gene of interest is complemented with
an episome or nutritional supplement, allowing genomic alleles to
be deleted |
shows the gene locus can be targeted for
deletion |
20 |
TUB, CRK1, NMT, SIR2, RPC2, TOPS, TXN1, GSH1, GLO1, SGT, DHS34, HSLV, NTR, TRYS, CYP51EIF4E,RAD51-3, RPIB, RAD9, LYSRS-1
|
1 |
NMT |
| *** |
unforced plasmid shuffle; plasmid
retained in the absence of antibiotic selection |
indirect
evidence for a gene being essential; best carried out in vivo |
12 |
PRT1, ODC, DHFR-TS, SPSDS, ADOMETDC, ARG, DHCH1, STI1, UMPS, CPS, UPRT
|
|
|
| **** |
forced plasmid shuffle or DiCre inducible deletion |
death of parasite after induction used as evidence of essentiality |
2 |
H2A.Z, H2B.V, MPK4
|
|
|
| ***** |
as above but with analysis
in amastigote stages and/or the mouse model |
application
to amastigotes provides best evidence for essentiality in vivo |
1 |
CRK3 |
|
|
